TY - JOUR
T1 - Selenium supplementation for patients with Graves' hyperthyroidism (the GRASS trial)
T2 - study protocol for a randomized controlled trial
AU - Watt, Torquil
AU - Cramon, Per
AU - Bjorner, Jakob Bue
AU - Bonnema, Steen Joop
AU - Feldt-Rasmussen, Ulla
AU - Gluud, Christian
AU - Gram, Jeppe
AU - Hansen, Jane Lindschou
AU - Hegedüs, Laszlo
AU - Knudsen, Nils
AU - Bach-Mortensen, Pernille
AU - Nolsöe, Rúna
AU - Nygaard, Birte
AU - Pociot, Flemming
AU - Skoog, Maria
AU - Winkel, Per
AU - Rasmussen, Aase Krogh
PY - 2013
Y1 - 2013
N2 - Graves' hyperthyroidism is an autoimmune disease causing hyperfunction of the thyroid gland. The concentration of selenium is high in the thyroid gland and two important groups of enzymes within the thyroid are selenoproteins, that is, they depend on selenium. Selenium may have beneficial effects on autoimmune hypothyroidism and on Graves' orbitopathy, but the effects of selenium on Graves' hyperthyroidism is unknown.We hypothesize that adjuvant selenium may be beneficial in the treatment of Graves' hyperthyroidism. The objective is to investigate if selenium supplementation plus standard treatment with anti-thyroid drugs versus standard treatment with anti-thyroid drugs will lead to a decrease in anti-thyroid drug treatment failure (that is, failure to remain euthyroid, without further treatment, one year after cessation of anti-thyroid drug treatment), faster and longer lasting remission (that is, anti-thyroid drug treatment success), and improved quality of life in patients with Graves' hyperthyroidism.
AB - Graves' hyperthyroidism is an autoimmune disease causing hyperfunction of the thyroid gland. The concentration of selenium is high in the thyroid gland and two important groups of enzymes within the thyroid are selenoproteins, that is, they depend on selenium. Selenium may have beneficial effects on autoimmune hypothyroidism and on Graves' orbitopathy, but the effects of selenium on Graves' hyperthyroidism is unknown.We hypothesize that adjuvant selenium may be beneficial in the treatment of Graves' hyperthyroidism. The objective is to investigate if selenium supplementation plus standard treatment with anti-thyroid drugs versus standard treatment with anti-thyroid drugs will lead to a decrease in anti-thyroid drug treatment failure (that is, failure to remain euthyroid, without further treatment, one year after cessation of anti-thyroid drug treatment), faster and longer lasting remission (that is, anti-thyroid drug treatment success), and improved quality of life in patients with Graves' hyperthyroidism.
U2 - 10.1186/1745-6215-14-119
DO - 10.1186/1745-6215-14-119
M3 - Journal article
C2 - 23782950
SN - 1745-6215
VL - 14
SP - 119
JO - Trials
JF - Trials
ER -